Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02776072 · ClinicalTrials.gov registry record
Observational Study to Characterize Real-world Clinical Outcomes With Relapsing-remitting Multiple Sclerosis (RRMS)
A clinical trial, sponsored by Biogen.
- Completed
- Registry status
- 2,978
- Enrollment target
NCT02776072 is a clinical trial that has completed, run by Biogen. The registered enrollment target is 2,978 participants.
The verdict
NCT02776072 has completed, sponsored by Biogen.
- COMPLETED
- Registry status
- 2,978 participants
- Enrollment target
Study Summary
The primary objective of the study is to evaluate the real-world clinical effectiveness, as measured by the proportion of participants relapsed at 12 months, in participants treated with dimethyl fumarate (DMF). Secondary objectives of the study are: To evaluate the real-world clinical effectiveness, as measured by the proportion of participants relapsed at 12 months, in participants treated with DMF, glatiramer acetate (GA), teriflunomide, or fingolimod both in the overall participant cohort and in a subset of participants who were naïve to disease-modifying therapy (DMT) and were diagnosed with multiple sclerosis (MS) within 3 years of starting the index therapy; To compare relapse activity, defined as annualized relapse rate (ARR), among participants treated with DMF, GA, teriflunomide, or fingolimod; To compare MS-related hospitalizations among participants treated with DMF, GA, teriflunomide, or fingolimod; To compare intravenous corticosteroid use among participants treated with DMF, GA, teriflunomide, or fingolimod.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2,978 participants |
| Start Date | 2016-05 |
| Est. Completion | 2016-12 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02776072
The ClinicalTrials.gov registry entry for NCT02776072 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 2,978 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Biogen, which has 334 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 0 interventions.
NCT02776072 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02776072 about?
NCT02776072 is a clinical study titled "Observational Study to Characterize Real-world Clinical Outcomes With Relapsing-remitting Multiple Sclerosis (RRMS)". The primary objective of the study is to evaluate the real-world clinical effectiveness, as measured by the proportion of participants relapsed at 12 months, in participants treated with dimethyl fumarate (DMF). Secondary objectives of the study are: To evaluate the real-world clinical effectivenes...
What is the current status of trial NCT02776072?
This trial is currently completed. The enrollment target is 2,978 participants. The study started on 2016-05. Estimated completion is 2016-12.
Who is sponsoring clinical trial NCT02776072?
This trial is sponsored by Biogen, which has 334 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.